Divis Laboratories Ltd
DIVISLABBSE 532488PharmaceuticalsMkt cap ₹2,46,737 Cr
Whole group, including subsidiaries — the figures companies headline.
Revenue · Q1 FY27
₹3,080 Cr
YoY +27.8%QoQ +8.8%
Net profit · Q1 FY27
₹902 Cr
YoY +65.5%QoQ +20.1%
Net margin · Q1 FY27
29.3%
+6.7 pts vs Q1 FY26
Net profit · FY26
₹2,568 Cr
YoY +17.2%
Quarterly results
| ₹ Cr | Q1 FY27 Apr–Jun 2026 | Q4 FY26 Jan–Mar 2026 | Q3 FY26 Oct–Dec 2025 | Q2 FY26 Jul–Sep 2025 | Q1 FY26 Apr–Jun 2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | 3,080 | 2,831 | 2,604 | 2,715 | 2,410 | +27.8% |
| Other income | 64.00 | 155 | 88.00 | 145 | 119 | -46.2% |
| Total income | 3,144 | 2,986 | 2,692 | 2,860 | 2,529 | +24.3% |
| Profit before tax | 1,180 | 963 | 780 | 912 | 733 | +61.0% |
| Tax | 278 | 212 | 197 | 223 | 188 | +47.9% |
| Net profit | 902 | 751 | 583 | 689 | 545 | +65.5% |
| Net margin | 29.3% | 26.5% | 22.4% | 25.4% | 22.6% |
Annual results
| ₹ Cr | FY26 Apr 2025–Mar 2026 | FY25 Apr 2024–Mar 2025 | FY24 Apr 2023–Mar 2024 | FY23 Apr 2022–Mar 2023 | FY22 Apr 2021–Mar 2022 | YoY |
|---|---|---|---|---|---|---|
| Revenue | 10,560 | 9,360 | 7,845 | 7,768 | 8,960 | +12.8% |
| Other income | 507 | 352 | 339 | 345 | 114 | +44.0% |
| Total income | 11,067 | 9,712 | 8,184 | 8,112 | 9,074 | +14.0% |
| Profit before tax | 3,388 | 2,916 | 2,163 | 2,369 | 3,684 | +16.2% |
| Tax | 820 | 725 | 563 | 545 | 723 | +13.1% |
| Net profit | 2,568 | 2,191 | 1,600 | 1,823 | 2,960 | +17.2% |
| Net margin | 24.3% | 23.4% | 20.4% | 23.5% | 33.0% |
BIC's take
We haven't covered Divis Laboratories Ltd yet. Browse our sector reports →
Source: BSE filings · Data as of 2 Oct 2026, 5:37 pm IST· ₹ crore unless stated. Covers BSE 500 companies only. Consolidated figures include subsidiaries; standalone is the parent company alone. Growth is shown only against a positive base. Not investment advice — check the company's full filing before acting.